Detalhe da pesquisa
1.
Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [18F]FET PET in patients with suspected recurrent anaplastic astrocytoma and glioblastoma.
Eur J Nucl Med Mol Imaging
; 49(13): 4677-4691, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35907033
2.
Nivolumab reaches brain lesions in patients with recurrent glioblastoma and induces T-cell activity and upregulation of checkpoint pathways.
Cancer Immunol Res
; 2024 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38885356
3.
The Neurogenome study: Comprehensive molecular profiling to optimize treatment for Danish glioblastoma patients.
Neurooncol Adv
; 5(1): vdad137, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38089638
4.
Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation.
Neurooncol Adv
; 4(1): vdac157, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36325372
5.
A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution.
Front Oncol
; 11: 597587, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33718145
6.
Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling.
Cancer Invest
; 28(8): 775-87, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20504227
7.
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Acta Oncol
; 48(1): 52-8, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19031176
8.
Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Anticancer Res
; 33(4): 1657-60, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23564811
9.
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
Expert Opin Pharmacother
; 12(5): 825-33, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21385110
10.
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Neuro Oncol
; 12(5): 508-16, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20406901
11.
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.
APMIS
; 118(8): 585-94, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20666740